To Study Whether Zinc Supplement Has Got Any Beneficial Effect In Neonatal Hyperbilirubinemia.

Not yet recruiting

Conditions: Neonates with neonatal hyperbilirubinemia within phototherapy range.

Registration Number: CTRI/2018/08/015245

Lead Sponsor: Tejas Hukumchand Mandlecha

Brief Summary: Zinc is one of the essential component in neonatal growth, protein synthesis and many other pathway. It has been shown to lower the serum Bilirubine level by inhibition of normal enterohepatic cycling of unconjugated bilirubin. Therefore, the anticipated role of oral zinc supplementation in neonatal jaundice seems to be attractive. This radamised clinical trial will be conducted on term neonate to characterize the role of zinc sulfate in neonatal hyperbilirubinemia.

Detailed Description: Not available

Recruitment & Eligibility

Status: Not Yet Recruiting

Sex: All

Target Recruitment: 90

Inclusion Criteria

All term neonate(>38wk) presented with indirect hyperbilirubinemia within phototherapy range.

Exclusion Criteria

1- Preterm neonate 2- neonates with DIRECT HYPERBILIRUBINEMIA 3 â€“ neonate requiring EXCHAGE TRANSFUSION at any point of time during study 4.All cases with Sepsis at the time of enrollment, severe respiratory disease requiring mechanical ventilation, congenital anomalies 5-patient who refuses to continue are excluded from study.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To Study Role Of Oral Zinc Sulphate Supplementation In Reduction Of Indirect Hyperbilirubinemia Term Neonate (more than 38 wk).	Use Of Zinc Till The Reduction Of Serum Bilirubine Below Phototherapy Range.

Secondary Outcome Measures

Name	Time	Method
1.TO STUDY THE EFFECT OF ORAL ZINC SULPHATE IN EARLY DISCHARGE IN TERM NEONATE(38).	2.TO STUDY SIDE EFFECTS OF ZINC SUPPLEMENTATION

Trial Locations

Locations (1): GOVERNMENT MEDICAL COLLAGE AURANGABAD
🇮🇳
Aurangabad, MAHARASHTRA, India
GOVERNMENT MEDICAL COLLAGE AURANGABAD
🇮🇳Aurangabad, MAHARASHTRA, India
Tejas Hukumchand Mandlecha
Principal investigator
7588531896
tejasjain17@gmail.com